title: [Internal medical therapy of gastrointestinal stroma tumors].
abstract: Until recently no active treatment for advanced or metastatic gastrointestinal stroma tumors (GIST) was available. The tyrosine kinase inhibitor imatinib has revolutionized the treatment of this disease and the median overall survival now reaches 5 years. The standard dose of imatinib is 400 mg per day. Locally advanced GIST should be treated with systemic therapy prior to surgical resection. Imatinib was recently licensed for adjuvant therapy following complete surgical removal of GIST in patients with a significant risk of recurrence.
authors.affiliation: Klinik für Innere Medizin III, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Bad Saarow, Pieskower Strasse 33, Bad Saarow, Germany. peter.reichardt@helios-kliniken.de
authors.forename: P
authors.initials: P
authors.lastname: Reichardt
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D018450:Disease Progression; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D015507:Drugs, Investigational; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use*; D020360:Neoadjuvant Therapy; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001549:Benzamides; D015507:Drugs, Investigational; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000077210:Sunitinib
references.citation: Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34
references.pmid: 15451219
references.citation: Eur J Cancer. 2005 Aug;41(12):1751-7
references.pmid: 16098458
references.citation: J Clin Oncol. 2008 Apr 20;26(12):2052-3; author reply 2053-4
references.pmid: 18421060
references.citation: J Clin Oncol. 2008 Feb 1;26(4):620-5
references.pmid: 18235121
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3141-7
references.pmid: 19451435
references.citation: Hum Pathol. 2002 May;33(5):459-65
references.pmid: 12094370
references.citation: Lancet. 2009 Mar 28;373(9669):1097-104
references.pmid: 19303137
references.citation: J Clin Oncol. 2008 Feb 1;26(4):626-32
references.pmid: 18235122
references.citation: Ann Oncol. 2009 May;20 Suppl 4:64-7
references.pmid: 19454466
references.citation: N Engl J Med. 2002 Aug 15;347(7):472-80
references.pmid: 12181401
references.citation: J Clin Oncol. 2007 Mar 20;25(9):1107-13
references.pmid: 17369574
references.citation: Lancet. 2006 Oct 14;368(9544):1329-38
references.pmid: 17046465
references.citation: Semin Diagn Pathol. 2006 May;23(2):70-83
references.pmid: 17193820